Notis McConarty Edward bought a new stake in shares of Stryker Corporation (NYSE:SYK – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,106 shares of the medical technology company’s stock, valued at approximately $978,000.
Several other hedge funds and other institutional investors also recently modified their holdings of SYK. Gables Capital Management Inc. purchased a new stake in Stryker in the second quarter worth about $25,000. Godfrey Financial Associates Inc. bought a new stake in Stryker during the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker during the 3rd quarter worth approximately $27,000. Finally, Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter worth approximately $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. Finally, Evercore set a $350.00 price target on shares of Stryker in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $386.28.
Stryker Stock Up 2.7%
SYK stock opened at $340.20 on Thursday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $130.49 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The business has a 50 day moving average of $326.19 and a 200 day moving average of $332.95.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.
Insider Transactions at Stryker
In related news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 315,370 shares of company stock valued at $98,463,501 in the last quarter. 4.60% of the stock is owned by insiders.
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
